Insmed Q2 Revenue Soars 296% to $425.5M; BRINSUPRI Guidance Raised to $1.25B–$1.4B
INSM sits 34% above its 52-week low of $90.39.
Summary
Insmed reported Q2 2026 revenue of $425.5M, a 296% increase year-over-year, and raised full-year BRINSUPRI guidance to $1.25B–$1.4B. The company now expects peak sales of over $14B across its three lead programs and is on track for cash flow positivity in 2027.
Key Events · Earnings and Guidance · INSM
-
Q2 Revenue Beat
Total revenues of $425.5M, up 296% YoY, driven by BRINSUPRI ($309.2M, +49% QoQ) and ARIKAYCE ($116.3M, +8% YoY).
-
BRINSUPRI Guidance Raised
Full-year 2026 BRINSUPRI revenue guidance increased to $1.25B–$1.40B from 'greater than $1B', reflecting strong launch momentum.
-
Peak Revenue Estimate Lifted
Combined peak revenue estimate for BRINSUPRI, TPIP, and ARIKAYCE raised to >$14B (BRINSUPRI >$7B, TPIP >$6B, ARIKAYCE >$1B).
-
Near-Breakeven Quarter
Net loss narrowed to $13.2M ($0.06/share) from $321.7M ($1.70/share) YoY, with operating loss of just $1.5M.
Analysis · INSM · Life Sciences
A massive Q2 beat underscores Insmed's transformation into a commercial powerhouse. Total revenues reached $425.5M, nearly quadrupling the prior year, fueled by the blockbuster launch of BRINSUPRI. Full-year BRINSUPRI guidance was raised to $1.25B–$1.4B, and the combined peak revenue estimate for three lead assets now exceeds $14B. The net loss narrowed dramatically to just $13.2M, and management reiterated a path to cash flow positivity in 2027 without additional capital.
At the time of this filing, INSM was trading at $121.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.5B. The 52-week trading range was $90.39 to $212.75. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.